Brokers issue forecasts for Avid Bioservices, Inc.’s earnings. in Q1 2026 (NASDAQ:CDMO)

Avid Bioservices, Inc. (NASDAQ:CDMO – Free Report ) – Stock analysts at William Blair issued their Q1 2026 earnings estimates for Avid Bioservices in a research note issued on Tuesday, September 10th. William Blair analyst M. Smock expects that the biopharmaceutical company will post earnings per share of ($0.04) for the quarter. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Avid Bioservices’ current year earnings is ($0.31) per share. William Blair also issued estimates for Avid Bioservices’ Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.03) EPS and Q4 2026 earnings at $0.01 EPS.

Avid Bioservices (NASDAQ:CDMO – Get Free Report ) last posted its earnings results on Tuesday, July 2nd. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.10). Avid Bioservices had a negative return on equity of 16.53% and a negative net margin of 101.26%. The firm had revenue of $42.98 million during the quarter, compared to the consensus estimate of $42.60 million.

Several other equities analysts have also commented on the company. Stephens reissued an “overweight” rating and set a $12.00 price objective on shares of Avid Bioservices in a research report on Tuesday. Royal Bank of Canada boosted their price objective on Avid Bioservices from $8.00 to $12.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, StockNews.com raised Avid Bioservices to a “sell” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Moderate Buy” and an average target price of $13.50, based on data from MarketBeat.

Check out our latest report on CDMOs

Avid Bioservices Stock Performance

Shares of CDMO stock opened at $11.16 on Thursday. The stock has a fifty day moving average of $9.97 and a 200 day moving average of $8.35. Avid Bioservices has a 52-week low of $4.07 and a 52-week high of $11.57. The firm has a market cap of $711.90 million, a price-to-earnings ratio of -5.05 and a beta of 1.37. The company has a quick ratio of 0.31, a current ratio of 1.46, and a debt-to-equity ratio of 2.74.

Indoor activity

In other news, CEO Nicholas Stewart Green sold 7,657 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $7.54, for a total transaction of $57,733.78. Following the completion of the transaction, the chief executive officer now directly owns 212,314 shares in the company, valued at $1,600,847.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available via this hyperlink. Insiders have sold 9,216 shares of company stock worth $69,984 over the last three months. 2.39% of shares are currently owned by corporate insiders.

Hedge funds influence Avid Bioservices

Several institutional investors and hedge funds have recently modified their holdings of CDMO. 12 West Capital Management LP bought a new stake in Avid Bioservices in the 1st quarter worth about $18,425,000. Point72 Asset Management LP boosted its holdings in Avid Bioservices by 51.2% in the second quarter. Point72 Asset Management LP now owns 2,673,050 shares of the biopharmaceutical company’s stock worth $19,086,000 after purchasing an additional 904,733 shares in the last quarter. American Century Companies Inc. boosted its holdings in Avid Bioservices by 5,631.6% in the second quarter. American Century Companies Inc. now owns 726,193 shares of the biopharmaceutical company’s stock worth $5,185,000 after buying an additional 713,523 shares during the last quarter. Millennium Management LLC boosted its holdings in Avid Bioservices by 15.8% in the second quarter. Millennium Management LLC now owns 5,099,529 shares of the biopharmaceutical company’s stock worth $36,411,000 after buying an additional 695,512 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Avid Bioservices by 27.1% in the 4th quarter. Wellington Management Group LLP now owns 1,478,842 shares of the biopharmaceutical company’s stock worth $9,612,000 after bought an additional 315,600 shares in the last quarter. 97.16% of shares are currently owned by institutional investors.

Avid Bioservices Company Profile

(Get a free report)

Avid Bioservices, Inc operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industry in the United States. Provides process development and clinical and commercial manufacturing services for biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, submission and regulatory assistance, upstream and downstream development and optimization, development of analytical methods, cells. line development, testing and characterization services.

See Also

Get daily news and reviews for Avid Bioservices – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Avid Bioservices and related companies with MarketBeat.com ‘s FREE daily email newsletter.